PT-141 is the development code associated with bremelanotide. A free-base peptide, its acetate form and the approved finished injection are related records, but they are not interchangeable materials.
Evidence at a glance
- PubChem lists bremelanotide free base as a cyclic seven-residue peptide with molecular weight 1025.2 g/mol.
- DailyMed lists bremelanotide acetate as the ingredient delivering 1.75 mg bremelanotide in 0.3 mL of the approved finished product.
- Regulatory approval applies to the named formulation, manufacturer and labeling—not to every material using PT-141 as a synonym.
Identity record
The PubChem peptide record includes an N-acetylated cyclic sequence with a D-phenylalanine residue. Sequence order, cyclization and stereochemistry all contribute to identity; a short marketing name does not capture them.
Analytical and evidence boundary
Acetate content changes formula-weight and content calculations. A certificate should state whether the result is reported on a free-base, acetate or as-is basis.
Never borrow the Vyleesi indication or safety profile as proof that a catalog lot is therapeutically equivalent. The appropriate connection is an evidence-context link with a prominent finished-drug boundary.
Editorial rule
State the exact material, form, model or population and endpoint supported by the cited record. Do not convert mechanistic plausibility, an animal result, a finished-drug label or an analytical test into a claim about an unrelated catalog lot.
Sources & editorial method
The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, study size, model/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- RECONNECT bremelanotide phase 3 trialsPrimary phase 3 publication; PMID 31599840.
- DailyMed Vyleesi prescribing informationCurrent FDA-approved finished-drug label.
- PubChem Bremelanotide recordFree-base peptide identity; CID 9941379.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
